Related Experiment Video
Updated: Aug 29, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Photodynamic therapy for sarcoma pulmonary metastases: a preclinical toxicity study
Timothy M Anderson1, Thomas J Dougherty, Dongfeng Tan
1Division of Thoracic Surgery, Roswell Park Cancer Institute, State University of New York, Elm & Carlton Streets, Buffalo, New York 14263, USA. timothy.anderson@roswellpark.org
Background:
Intraoperative pleural and interstitial PDT accompanying resection may reduce peripheral micrometastatic foci and preclude lobectomy when applied to hilar lesions.
Materials And Methods:
Fourteen beagles were used to determine the safety and histologic changes resulting from PDT. Photosensitizers HPPH (0.3 mg/kg) or Photofrin (2.0 mg/kg) were administered i.v. 48 hours prior to thoracotomy and light delivery. At thoracotomy interstitial or pleural light was given. They underwent necropsy at eight and 30 days.
Results:
The significant toxicitities occurred with pleural PDT using high dose HPPH (15 & 30 J/cm2) including pyrexia, elevated WBC and CPK, and respiratory distress. However, using single beam pleural surface treatment all light doses for HPPH and Photofrin (5-40 J/cm2) were tolerated with depths of treatment effect up to 10 mm with HPPH.
Conclusion:
Histologic and clinical changes associated with interstitial and pleural PDT were acceptable after dosimetry was adjusted. PDT holds promise as an adjuvant treatment for sarcoma pulmonary metastases.
